Adalimumab – USA

Adalimumab – USA

Decision on IPR:

AIA Review
Filing Date
Institution Date
Petitioner
US Patent
Respondent
Status
IPR2016-00408
&
IPR2016-00409
12/29/2015
07/07/2016
Boehringer Ingelheim GmbH
8,889,135
AbbVie Biotechnology Ltd.
Final Written Decision – Jul 6, 2017
(Claims 1-5 are unpatentable)

The ’135 patent, titled “Methods of Administering Anti-TNFα Antibodies,” issued on November 18, 2014. The ’135 patent discloses methods of treating rheumatoid arthritis (“RA”) with a human anti-tumor necrosis factor α (“TNFα”) antibody.

Leave a Reply

Leave a Reply

Your email address will not be published.

Disclaimer
All content provided on this blog is for informational purposes only. By using the blog, you agree that the information on this blog does not constitute legal or other professional advice on author's or on his company's behalf.

Copyrights 2022 Pharma IP Circle. All Rights Reserved